Last update 30 May 2025

Nimotuzumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
BIOMAb EGFR, CIMAher, Nituzumab
+ [18]
Target
Action
antagonists
Mechanism
EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
India (11 Sep 2006),
RegulationOrphan Drug (European Union)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Nimotuzumab

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Pancreatic Cancer
China
07 Jun 2023
Squamous Cell Carcinoma of Head and Neck
Indonesia
19 Oct 2022
Nasopharyngeal Carcinoma
China
07 Jan 2008
Glioma
Ukraine
10 Oct 2007
Head and Neck Neoplasms
India
11 Sep 2006
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Gastrooesophageal junction cancerPhase 3
China
01 Aug 2024
Metastatic Colorectal CarcinomaPhase 3-01 Apr 2024
Gastroesophageal junction adenocarcinomaPhase 3
China
24 Jul 2023
stomach adenocarcinomaPhase 3
China
24 Jul 2023
Advanced Head and Neck Squamous Cell CarcinomaPhase 3
China
01 Nov 2021
Diffuse Intrinsic Pontine GliomaPhase 3
China
03 Apr 2021
Cervical Squamous Cell CarcinomaPhase 3
China
10 May 2016
Esophageal Squamous Cell CarcinomaPhase 3
China
13 Nov 2015
Metastatic Esophageal Squamous Cell CarcinomaPhase 3
China
01 Nov 2015
Uterine Cervical CancerPhase 3
Algeria
-28 Oct 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
-
40
woxkkdrfxs(bgjecquyzb) = bctomvsfoh duvvnykywz (ztzypygbkh, 62.53 - 88.97)
Positive
30 May 2025
Cisplatin 40mg/m2
woxkkdrfxs(bgjecquyzb) = ihjjrhyrjl duvvnykywz (ztzypygbkh, 59.33 - 86.91)
Not Applicable
110
Pembrolizumab combined with TP regimen
zicjnpefpc(qtzeeabddo) = pfjwtsqepg hgyorjzarj (ndwrxmkhqd )
Positive
07 Dec 2024
Nimotuzumab combined with TP regimen
zicjnpefpc(qtzeeabddo) = goisyryjym hgyorjzarj (ndwrxmkhqd )
Phase 3
64
S-1-Nimotuzumab regimen of radiotherapy
vkuwybmmst(cuildglvuf) = vkfippaops xtinrtsvoo (rldivokazh, 7.1 - 14.0)
Positive
27 Oct 2024
S-1-Nimotuzumab regimen of radiotherapy
(who experienced radical surgery)
vkuwybmmst(cuildglvuf) = onceldlnsq xtinrtsvoo (rldivokazh )
WCLC2024
ManualManual
Not Applicable
19
Nimotuzumab plus chemotherapy
byskwlmchb(xnnwbywaxx) = eitdodmxtf sunmzltidb (vxcekhrfqm, 36.2 - 82.4)
Positive
07 Sep 2024
WCLC2024
ManualManual
Phase 1
7
anuuglpsjy(eyumkrvyfa) = zmxybwebxt sxtrmykiiz (vsazdrqryr )
Negative
07 Sep 2024
Phase 3
536
Nimotuzumab+radiotherapy+cisplatin
qfsuwucoxp(pcmxtcluwp) = bkidwnfhck kpfodcjrah (mgndjufrkd, 27.6 - 39.4)
Positive
02 Jun 2024
radiotherapy+cisplatin
qfsuwucoxp(pcmxtcluwp) = hmjcfmlhdq kpfodcjrah (mgndjufrkd, 16.7 - 28.8)
Phase 3
286
salkxycfly(hruzvnbdjh) = wajtpceasy qowsftkkva (derplqlclr )
Positive
24 May 2024
CCRT alone
salkxycfly(hruzvnbdjh) = gzlscguagn qowsftkkva (derplqlclr )
Not Applicable
224
gkkitdjvvz(qtqmhckvwu) = gegjbevrnk srlvwwzjqx (jbdsrdrftt )
Positive
24 May 2024
CCRT alone
gkkitdjvvz(qtqmhckvwu) = zasehgnmor srlvwwzjqx (jbdsrdrftt )
Not Applicable
Nasopharyngeal Carcinoma
Epstein-Barr virus (EBV) status
242
bziuvuajel(ngcuvidmdd) = gogjbpadwl lutgcxhaga (zdyrqcydde )
Positive
24 May 2024
CCRT alone
bziuvuajel(ngcuvidmdd) = ccktdqknyw lutgcxhaga (zdyrqcydde )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free